Market Wrap | Zip, A2 Milk, Nufarm, Transurban, SkinKandy, Worley, Nuix, Challenger
Market Wrap | Zip, A2 Milk, Nufarm, Transurban, SkinKandy, Worley, Nuix, Challenger
About this video
Buy now, pay later provider Zip has reaffirmed its full-year cash earnings target of 340 million dollars ahead of its annual general meeting today desipte taking a 10.1 million dollar hit from a US fraud event in the first quarter. While the coordinated fraud temporarily slowed new customer growth in July and August, US transaction volumes rebounded 41 per cent in September once enhanced security controls were put in place. First-quarter adjusted cash earnings rose 19.5 per cent to 75.1 million dollars, with Zip's board also recommending a five-for-one share consolidation and continuing to assess a potential dual listing.
A2 Milk reported steady progress in recovering its lost market share in China following supply disruptions, while maintaining its FY27 revenue and margin guidance. China-label infant formula offtake has recovered to approximately 50% of pre-disruption levels, improving from around 40% in August. The company expects further gradual recovery through new product launches. At its annual general meeting, A2 Milk said first-half FY27 revenue growth is tracking slightly below the prior corresponding period, with full-year sales expected to remain broadly flat. Underlying EBITDA margins are forecast at approximately 15%, with earnings heavily weighted towards the second half. Shares fell around 9.5% following the update.
Nufarm reported a strong FY26 earnings result for the year ended September, with underlying EBITDA increasing 25% to $378 million. Underlying net profit after tax reached almost $20 million, reversing the previous year's loss. Despite the improved financial performance, Nufarm shares came under significant selling pressure during the session.
Transurban reported October traffic growth of 0.7% across its network, measured by group average daily traffic. Sydney traffic increased approximately 0.5%, while North America delivered stronger growth of 13.2%.
SkinKandy reported a positive start to the financial year, with revenue increasing 21% across the first 19 weeks. The body-piercing studio operator said its newer locations are performing in line with expectations. The company has opened nine new studios across Australia and New Zealand so far this year and plans to open a further 20 locations over the full financial year, supporting its ongoing expansion strategy.
Worley faced a shareholder protest over its executive remuneration report at its annual general meeting, while long-serving chairman John Grill announced plans to step down next year. Despite ongoing disruption in the Middle East and softer demand across the European chemicals sector, the company reaffirmed its full-year outlook, targeting mid-to-high single-digit growth in both revenue and underlying earnings.
Nuix told shareholders at its annual general meeting that entering exclusive discussions with US private equity firm Haveli Investments is in their best interests. The proposed $2.75 per share cash offer represents a 73% premium to Nuix's share price before the takeover approach. The company continues to assess the proposal as discussions progress.
Japanese life insurance giant TAL has upped its offer for annuities provider Challenger from $11.80 to $12.20 per share, valuing the ASX-listed company at roughly $8.2 billion. But the board indicated it still “does not adequately represent fair value for Challenger shareholders in the context of a control transaction”. TAL owns roughly 20 per cent of Challenger already and is pushing to get full control."